[HTML] plos.org

[HTML][HTML] Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - Plos one, 2023 - journals.plos.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …
被引用次数：9 相关文章

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 subvariants …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - PLoS …, 2023 - ui.adsabs.harvard.edu
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …
[HTML] europepmc.org

[HTML][HTML] Lack of effectiveness of Bebtelovimab Monoclonal Antibody Among High-Risk Patients with SARS-Cov-2 Omicron During BA. 2, BA. 2.12. 1 and BA. 5 …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - 2022 - europepmc.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …

Lack of effectiveness of bebtelovimab monoclonal antibody among high-risk patients with SARS-CoV-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 subvariants …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - 2023 - cabidigitallibrary.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …

Lack of effectiveness of Bebtelovimab Monoclonal Antibody Among High-Risk Patients with SARS-Cov-2 Omicron During BA. 2, BA. 2.12. 1 and BA. 5 Subvariants …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - medRxiv, 2022 - medrxiv.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 subvariants …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - PloS …, 2023 - pubmed.ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 subvariants …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - PLoS …, 2023 - search.ebscohost.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …
[HTML] nih.gov

[HTML][HTML] Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - PLOS …, 2023 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA. 2, BA. 2.12. 1 and BA. 5 subvariants …

S Sridhara, AB Gungor, HK Erol, M Al-Obaidi… - Plos one, 2023 - europepmc.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are
expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real …